Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Inclusion Criteria: * Male or female ≥ 18 years of age * Recipient of their first kidney transplant from a living or deceased donor * Agree to comply with contraception requirements during and for at least 90 days after the last administration of study drug Exclusion Criteria: * Induction therapy, other than study assigned rATG, planned as part of initial immunosuppressive regimen * Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies * Currently treated with corticosteroids other than topical or inhaled corticosteroids * Will receive a kidney with an anticipated cold ischemia time of \> 30 hours * Will receive a kidney from a donor that meets any of the following: * 5a. Donation after Cardiac Death (DCD) criteria; Or * 5b. Kidney Donor Profile Index (KDPI) of \> 85%; Or * 5c. Is blood group (ABO) incompatible * Medical conditions that require chronic use of systemic corticosteroids or other immunosuppressants * History of a thromboembolic event, known hypercoagulable state, or condition requiring long term anticoagulation * Positive T- or B-cell crossmatch that is due to HLA antibodies or presence of a DSA at Screening